SCHEDULE: Wellington Management Reports 8.66% Stake in Apogee Therapeutics

Wellington Management Group LLP and its affiliates disclosed a beneficial ownership of 8.66% in Apogee Therapeutics, Inc. common stock as of December 31, 2025.

Summary

• Wellington Management Group LLP and its affiliated entities collectively reported beneficial ownership of 4,746,585 shares of Apogee Therapeutics, Inc. common stock.
• This represents 8.66% of the class of securities.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating a previous filing and an updated ownership position.
• The reporting persons include Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP.
• The securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Apogee Therapeutics, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive, as a significant stake by a reputable institutional investor like Wellington Management can instill confidence in the market regarding Apogee Therapeutics, Inc.'s prospects.

Positives

• A significant stake (8.66%) by a major institutional investor like Wellington Management can signal confidence in Apogee Therapeutics, Inc.'s long-term prospects.
• The holding is stated to be in the ordinary course of business, suggesting a passive investment rather than an activist stance that could introduce uncertainty.

Risks

• A large institutional holder could potentially divest a significant portion of its shares, which might put downward pressure on the stock price.
• While currently a passive investment, any future change in Wellington Management's investment strategy could impact the issuer.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a substantial stake by a prominent asset manager like Wellington Management often indicates a thorough due diligence process and a belief in the company's value proposition within its sector. For a company like Apogee Therapeutics, operating in the potentially volatile biotechnology or pharmaceutical space, such institutional backing can be viewed favorably by the market, suggesting a degree of stability and validation.

Stakeholder Impact

• Shareholders: Existing shareholders may view the significant institutional ownership as a positive signal, potentially leading to increased investor confidence and stability in the stock.
• Potential Investors: The presence of a major institutional investor like Wellington Management could attract other institutional and retail investors, validating Apogee Therapeutics, Inc. as an investment opportunity.

Key Dates

Recommendation

The filing indicates a significant, passive institutional stake by Wellington Management, which is generally a positive signal of confidence. However, a Schedule 13G filing primarily discloses ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It confirms a substantial existing investment, suggesting a 'hold' for investors who may already be considering or holding the stock, pending further operational updates from Apogee Therapeutics, Inc.

Keywords

Apogee Therapeutics, Wellington Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake